Condition: Refractory Ewing Sarcoma · Relapsed Ewing Sarcoma · Ewing Sarcoma · Sponsor: Jazz Pharmaceuticals
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@JazzPharma.com
Always discuss trial participation with your own doctor first.
| Children's Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| Lucile Packard Children's Hospital | Palo Alto, California, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Johns Hopkins All Children's Hospital | St. Petersburg, Florida, United States | Recruiting |
| Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Atlanta, Georgia, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Corewell Health | Grand Rapids, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05734066